2023-08-10 18:12:40 ET
- Akebia Therapeutics ( NASDAQ: AKBA ) said it will delay filing of its Q2 financial results due to accounting errors relating to recording and reporting of return reserves for Auryxia.
- However, the biopharma said that it is still on track to resubmit an NDA for vadadustat as a treatment for anemia due to chronic kidney disease this quarter as planned.
- Akebia ( AKBA ) also reiterated net product revenue guidance of $175M-$180M. The consensus for total revenue is $203.4M.
- The company also noted it believes it has enough cash on hand to fund operations through the next year.
For further details see:
Akebia delaying Q2 earnings filing; vadadustat Q3 NDA resubmission on track